Quote:Agreed. The company has a great pipeline of products!
Now if we just had some money to advance them.
OvaDx®, MSPrecise®, LymPro Test®
Theranostics Health customer list includes 7 of the top 10 pharmaceutical companies with estimated pharma services revenue of over $1.5 million in 2015 expected to grow significantly in the coming years...
THI currently generates over $1.5M in services revenue from some of the world's leading biopharmaceutical companies, including 7 of the top 10 pharmaceutical companies by revenue
THI has a CLIA lab where Amarantus' Diagnostics has established operations over the course of the first quarter that will allow for CLIA validation and commercial launch of the combined company's suite of high-value, proprietary diagnostics in the areas of oncology and neurology . THI's sales channel into the pharmaceutical industry will provide important leverage for the combined company to market the LymPro Test® for Alzheimer's disease. We could not have picked a better partner to bring Avant and Amarantus' Diagnostics leading-edge intellectual property in diagnostics and biomarkers to the market."
THI's CLIA laboratory provides the combined company with the infrastructure to launch OvaDx®, MSPrecise® and LymPro Test in a regulatory compliant environment that has been vetted by some of the world's top pharmaceutical companie
http://www.amarantus.com/news/press-releases/...to-combine
ESS – Severe Adult Burns ODD Granted
ESS is entering Phase 2 clinical studies under a CRADA agreement with the US Army
Amarantus announced that it has successfully completed the growth and testing components of its confirmatory engineering run as previously anticipated, and is now finalizing the documentation, sterilization validation, and auditing that is required to complete the technical transfer. Once technical transfer is finished, which is expected to be in the first quarter of 2016, Amarantus will be operationally ready to supply ESS for the planned Phase 2 clinical study for the treatment of full thickness thermal burns covering over 50% of the body with the US Army. The 10-patient trial will be conducted under a Collaborative Research & Development Agreement (CRADA) with the U.S. Army's Institute for Surgical Research (ISR) at Fort Sam Houston in Texas.
In October 2015, the Company decided to focus the majority of its available resources on the ESS program, due largely to the incredible need for this product in the marketplace - evidenced by the US Army's financial support and strong desire to open enrollment for the upcoming Phase 2 clinical study to treat U.S. soldiers who have been critically burned serving their country ," said Gerald E. Commissiong, President & CEO of Amarantus. "Today's announcement marks a major milestone towards the opening of this study.
http://www.amarantus.com/news/press-releases/...-update-on
Amarantus Appoints Brian E. Harvey, MD PhD to Strategic Advisory Board
"I am excited to help Amarantus accelerate regulatory interactions with the FDA for its diverse orphan drug portfolio of products," said Dr. Harvey. "ESS and Eltoprazine are moving into mid and late stage development across several niche indications where the standard of care has not seen any significant innovation in over 50 years. ESS is a product candidate that demands careful, focused clinical and regulatory execution in order to bring this life-saving treatment to market as expeditiously as possible. With respect to Eltoprazine and its recent Orphan designation, Amarantus has an opportunity to redefine the regulatory pathway to approval for Eltoprazine with its recent orphan drug designation, and we intend to engage the regulatory authorities in discussions as it relates to this pathway forward."
Cheers
6
1
